Margaret Galluzzi

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

J.C. Flowers & Co. LLC (J.C. Flowers & Co.) is a private equity firm founded in 1998 by J. Christopher Flowers. The firm is headquartered in New York.

Fordham University provides college and university. It offers undergraduate colleges and graduate & professional schools. The company was founded in 1841 and is headquartered in Bronx, NY.

MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom.

Institut Mines-Télécom provides information technology education services. It is an organization for higher education and research in the information and communication technologies and sciences. The firm also provides information technology education services. The company was founded in 1844 and is headquartered in Paris, France.

Part of American International Group, Inc., AIG Global Investment Group, Inc. provides investment advisory services. The company is based in New York, NY. The CEO of the company is Win Jay Neuger.

Capgemini Consulting SAS provides management consulting and outsourcing services. The firm advises and supports organizations in transforming their business. The company was founded on July 12, 2004 and is headquartered in Paris, France.

AXA Partners Holdings Ltd. provides accident, sickness, and unemployment insurance services. The company was founded on September 29, 2003 and is headquartered in London, the United Kingdom.

Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.

Part of Merck & Co., Inc., Sanofi Pasteur MSD Ltd. is a company based in Dublin, Ireland. The Irish company develops and produces vaccines.

Part of Merck & Co., Inc., Sanofi Pasteur MSD SA is a company based in Madrid, Spain. The Spanish company develops vaccines.

Roc SA provides housing development services.

Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company is based in Boston, MA. Servier Pharmaceuticals continues to build a treatment portfolio with a current focus on oncology within acute lymphoblastic leukemia. The company invests in innovative research and development through development or partnerships to best address the unmet needs of patients. Additionally, the company is proud to offer financial assistance to not only support patients and their families but a variety of focused advocacy groups and healthcare professionals as well. Servier Pharmaceuticals is committed to engaging with patients, caregivers, families, and patient organizations to ensure their voices are heard in every initiative. The company's responsibility is to help make the world a better place for patients and their families, and it strives to have consistent and concise transparency throughout all clinical trials and research and development for the benefit of all patients. The company was founded in 1954. The CEO is David K. Lee.

Part of PharmaEngine, Inc., Pharmaengine Europe SARL develops pharmaceutical products for cancer diseases. The company is based in Paris, France. The CEO of the French company is Alain Herrera.

M2care SAS is a French healthcare company founded in 2017. The company is based in Lyon, France. M2care is a team of passionate entrepreneurs who invest in human and financial value to co-found, co-operate, and co-develop innovative projects in the healthcare sector until they reach the patient.

Gustave Roussy Transfert is a subsidiary of Gustave Roussy, the first cancer control center in France, which places innovation at the heart of care and research against cancer. The private company is based in Villejuif, France. The French company's main mission is to identify, protect, promote, and support the scientific, technological, and medical resources of Gustave Roussy. Gustave Roussy Transfert has designed a program called "Better Living Cancer" to support cancer patients during and after treatments through complementary approaches and practices to improve their quality of life. The program includes physical activity sessions, mindfulness meditation courses, and aesthetic care.

EMERCell SAS is an oncology company based in Montpellier, France. The French company is focused on developing a platform technology to produce off-the-shelf allogenic natural killer (NK) cells. The company's lead drug candidate, NK-001, is intended for the treatment of lymphoma patients who are refractory to conventional therapies. EMERCell collaborates with numerous industrial and academic partners and has received support from the Occitanie region (ADI) and Bpifrance. The company was founded in 2013 by Patrick Henno and Martin Villalba and is a member of Eurobiomed.

Fight Cancer Global, LLC provides a network platform aimed at solving the isolation problems faced by cancer patients. The private company is based in Houston, TX.

Onward Therapeutics SA is a Swiss development stage oncology company that focuses on identifying innovative technologies and developing breakthrough medicines for cancer treatment. The private company was founded by Alain Herrera and is based in Biopole, Switzerland, a life sciences campus in Epalinges, near Lausanne. The company acquires licenses for potential development candidates and invests in partners with transformative technology platforms. Onward recently licensed a preclinical stage bispecific antibody targeting two immune checkpoints and invested in the series A financing round in Biomunex Pharmaceuticals SAS. Onward also has an affiliate in Montpellier, France, and an office in Boston.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.